[
  {
    "ts": null,
    "headline": "Eli Lilly & Co. stock outperforms competitors on strong trading day",
    "summary": "Eli Lilly & Co. stock outperforms competitors on strong trading day",
    "url": "https://finnhub.io/api/news?id=500d36dac91b549f3dc89b67d5894b24182ffcad539e1c51df9d2d6eebb31eed",
    "source": "MarketWatch",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1761150660,
      "headline": "Eli Lilly & Co. stock outperforms competitors on strong trading day",
      "id": 137225042,
      "image": "",
      "related": "LLY",
      "source": "MarketWatch",
      "summary": "Eli Lilly & Co. stock outperforms competitors on strong trading day",
      "url": "https://finnhub.io/api/news?id=500d36dac91b549f3dc89b67d5894b24182ffcad539e1c51df9d2d6eebb31eed"
    }
  },
  {
    "ts": null,
    "headline": "Guardant Health (GH) Is Up 7.9% After FDA Approval of Blood Test for Lilly’s Inluriyo",
    "summary": "Guardant Health received FDA approval for its Guardant360 CDx blood test as a companion diagnostic for Eli Lilly’s Inluriyo, targeting advanced breast cancer patients with ESR1 mutations. This regulatory milestone positions Guardant Health at the center of precision oncology, potentially enhancing both patient treatment options and the company's clinical impact. We'll explore how this FDA approval for Guardant360 CDx could reshape Guardant Health's investment narrative and growth...",
    "url": "https://finnhub.io/api/news?id=491158d9fcd4bbde1665a209c34e75218590b8609dbb884fb92a6d5412864145",
    "source": "Yahoo",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1761146199,
      "headline": "Guardant Health (GH) Is Up 7.9% After FDA Approval of Blood Test for Lilly’s Inluriyo",
      "id": 137187686,
      "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
      "related": "LLY",
      "source": "Yahoo",
      "summary": "Guardant Health received FDA approval for its Guardant360 CDx blood test as a companion diagnostic for Eli Lilly’s Inluriyo, targeting advanced breast cancer patients with ESR1 mutations. This regulatory milestone positions Guardant Health at the center of precision oncology, potentially enhancing both patient treatment options and the company's clinical impact. We'll explore how this FDA approval for Guardant360 CDx could reshape Guardant Health's investment narrative and growth...",
      "url": "https://finnhub.io/api/news?id=491158d9fcd4bbde1665a209c34e75218590b8609dbb884fb92a6d5412864145"
    }
  },
  {
    "ts": null,
    "headline": "NVO Stock Falls Amid Governance Shift as Foundation Seeks New Board",
    "summary": "Novo Nordisk stock slides as the Novo Nordisk Foundation pushes a sweeping board overhaul, signaling a new era in governance and strategic direction.",
    "url": "https://finnhub.io/api/news?id=d482ac4579a3a86bd6961ee1b1e2f5d35149d1887fd42e679636d8fdb524dc3f",
    "source": "Yahoo",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1761145440,
      "headline": "NVO Stock Falls Amid Governance Shift as Foundation Seeks New Board",
      "id": 137187688,
      "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
      "related": "LLY",
      "source": "Yahoo",
      "summary": "Novo Nordisk stock slides as the Novo Nordisk Foundation pushes a sweeping board overhaul, signaling a new era in governance and strategic direction.",
      "url": "https://finnhub.io/api/news?id=d482ac4579a3a86bd6961ee1b1e2f5d35149d1887fd42e679636d8fdb524dc3f"
    }
  },
  {
    "ts": null,
    "headline": "3 Things Investors Need to Know Ahead of Eli Lilly's Q3 Earnings Report",
    "summary": "The rapid growth rates of recent years aren't guaranteed to continue.",
    "url": "https://finnhub.io/api/news?id=7f790113273f8d4924c2bbf6bbb3a2131c5b23d22110132345c40e4f34d47e3a",
    "source": "Yahoo",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1761118980,
      "headline": "3 Things Investors Need to Know Ahead of Eli Lilly's Q3 Earnings Report",
      "id": 137187689,
      "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
      "related": "LLY",
      "source": "Yahoo",
      "summary": "The rapid growth rates of recent years aren't guaranteed to continue.",
      "url": "https://finnhub.io/api/news?id=7f790113273f8d4924c2bbf6bbb3a2131c5b23d22110132345c40e4f34d47e3a"
    }
  },
  {
    "ts": null,
    "headline": "US pharma price probe raises threat of new drug tariffs",
    "summary": "Donald Trump’s administration is stepping up attacks on US trading partners over drug pricing, preparing a new probe that would lay the ground...",
    "url": "https://finnhub.io/api/news?id=6d823f1133102d999d6166b7c0a2bd9d62d65b778cbcd1a5ede2991491173b39",
    "source": "Yahoo",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1761105630,
      "headline": "US pharma price probe raises threat of new drug tariffs",
      "id": 137187690,
      "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
      "related": "LLY",
      "source": "Yahoo",
      "summary": "Donald Trump’s administration is stepping up attacks on US trading partners over drug pricing, preparing a new probe that would lay the ground...",
      "url": "https://finnhub.io/api/news?id=6d823f1133102d999d6166b7c0a2bd9d62d65b778cbcd1a5ede2991491173b39"
    }
  },
  {
    "ts": null,
    "headline": "Eli Lilly and Company (LLY): A Bull Case Theory",
    "summary": "We came across a bullish thesis on Eli Lilly and Company on Kontra Investments’s Substack by Kontra. In this article, we will summarize the bulls’ thesis on LLY. Eli Lilly and Company’s share was trading at $724.54 as of September 26th. LLY’s trailing and forward P/E were 47.36 and 24.04 respectively according to Yahoo Finance. Few companies […]",
    "url": "https://finnhub.io/api/news?id=6f35ea6f29f88f4b4f08d4e32ee1bf401dcd79b1b13c4db2d619ac8dd14dee27",
    "source": "Yahoo",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1761092378,
      "headline": "Eli Lilly and Company (LLY): A Bull Case Theory",
      "id": 137187691,
      "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
      "related": "LLY",
      "source": "Yahoo",
      "summary": "We came across a bullish thesis on Eli Lilly and Company on Kontra Investments’s Substack by Kontra. In this article, we will summarize the bulls’ thesis on LLY. Eli Lilly and Company’s share was trading at $724.54 as of September 26th. LLY’s trailing and forward P/E were 47.36 and 24.04 respectively according to Yahoo Finance. Few companies […]",
      "url": "https://finnhub.io/api/news?id=6f35ea6f29f88f4b4f08d4e32ee1bf401dcd79b1b13c4db2d619ac8dd14dee27"
    }
  }
]